This Is The Label For Divalproex Sodium Delayed-release Tablets, Usp 500 mg 30 Tablets. (Divalpoex Sod 500mg Qualitest)
Divalproex Sodium
Product Images NDC 53808-0681
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Divalproex Sodium (NDC 53808-0681). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by State Of Florida Doh Central Pharmacy, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Structural Formula Of Divalproex Sodium Delayed Release Tablets. (Divalproexdr 1)
Figure 1. Percentage Of Patients Achieving ≥ 30% Reduction In Symptom Score From Baseline (Divalproexdr 2)
The text describes the percentage of patients achieving more than a 30% reduction in symptoms compared to their baseline, represented in Figure 1. The data from Study 1 and 2 are shown for treatments with placebo and divalproex sodium. The asterisk (*) denotes statistical significance with p<0.05.*
Figure 2 (Divalproexdr 3)
This appears to be a chart showing the percentage reduction in CPS (cycles per second) rate for divalproex sodium versus a placebo. The chart displays various percentages ranging from -100% to 100%. Additionally, there is a bar graph displaying the percentage of patients who experienced improvement, no change, or worsening of symptoms with divalproex sodium.*
Figure 3 (Divalproexdr 4)
The text is a graph showing the reduction in CPS (Central Precocious Puberty) rate with two different drug doses. The graph has different percentage values ranging from 100% to -100%, along with a scale showing the percentage of patients who experienced improvement, no change or worsening.*
Figure 4. Mean 4-week Migraine Rates (Divalproexdr 5)
The figure shows the mean 4-week migraine rates for Placebo and Divalproex Sodium in Study 1 and Study 2. The mean dose of Divalproex Sodium was either 500 or 1,000 mg/day in Study 2, while in Study 1 it was 1,087 mg/day.*
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
